Vigil Neuroscience Announced An Update Following A Type C Meeting With The FDA To Its Clinical Development Strategy For Its IGNITE Trial Of Iluzanebart For Adult-onset Leukoencephalopathy With Axonal Spheroids And Pigmented Glia
$VIGL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
The Company plans to report the final analysis from the IGNITE clinical trial, including all patients at 12 months dosed with either 20 mg/kg or 40 mg/kg of iluzanebart in the first half of 2025.